Time is running out to register for the joint ICR/ABPI seminar 'Smarter drug development - delivering the science' running from 16 to 17 November at the Crowne Plaza Hotel, Heathrow, London
The meeting is aimed at all those involved in exploratory clinical development within pharmaceutical companies, CROs and academia; including clinicians, project managers, CRAs, senior mangers, regulatory authority personnel and ethics committee members.
The two day course considers the challenges and opportunities in exploratory drug development and topics include:.
European initiatives to meet the challenge of delivering better medicines in a smart manner.
The use of biomarkers and dose predictions in early phase drug development.
The use of 'omics' with a focus on proteomics.
Proof of concept and statistical models for predicting safety and efficacy.
A regulatory and biotech perspective of smarter drug development.
The needs of patients and prescribers in drug development.
There will also be a debate on the statement: 'Non therapeutic studies should be performed in children during early drug development'.
Presenters include Prof Sir Colin Dollery, Prof Michael Rawlins (Nice) and many other key representatives from the pharmaceutical industry and academia during what the organiser says promises to be a relevant, varied and essential event for everyone with an interest in this important area.
